Skip to content

Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France

Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05717491
Acronym
PREVENDIAB
Enrollment
2014
Registered
2023-02-08
Start date
2021-12-14
Completion date
2024-03-31
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, PreDiabetes

Keywords

(Pre) diabetes, Risk factors, Precarious, Accelerated aging

Brief summary

Populations in precarious situations or with low socio-economic status have an increased risk of diabetes and accelerated aging. According to the population studied, the elements that can explain these health inequalities are not unequivocal and remain poorly known. The north of France, particularly affected by socio-economic disparities, has a prevalence of diabetes among the highest in metropolitan France. This is why investigators want to study the clinical, biological, social and behavioural risk factors of the entry into diabetes and accelerated aging among a large population in the North of France. This study aims to characterize the population (among which a majority (55%) suffers from precarious conditions) who come to carry out their health examination at the Pasteur Institute in Lille in order to study the risk factors to better explain these health inequalities. This research consists of a main descriptive observational, cross-sectional study carried out on 2233 volunteers (main group) over 18 months, and a complementary analytical case-control study that will be offered to 216 participants (sub-group).

Detailed description

Primary Objective : Assessment of Prevalence of Prediabetes and Diabetes by Socio-Economic Status Primary efficacy endpoint : Fasting glucose value based on EPICES score : Glycemia: * Normal: fasting glucose ≤ 1g/l * Prediabetes: fasting glucose \>1 g/l and ≤1.25 g/l * Diabetes: fasting glucose \>1.25 g/l EPICES score: quintiles of score distribution (Q1 to Q5) Secondary Objectives specific to the main group: * Characterize the population and analyze the risk factors (clinical, biological, socio-economic and behavioural) of diabetes and prediabetes in this population. * Study the level of biological ageing and factors associated with accelerated ageing. * Estimate the risk of (pre)diabetes and accelerated aging based on socio-economic profile. Secondary Objectives specific to the sub-group: * Assess the impact of economic, social and cultural capital on health in terms of diabetes and accelerated aging. * Analyze the effect on diabetes and accelerated aging of the exposures assessed: body composition, physical activity, arterial rigidity, cognitive status, psychiatric disorders, fragility, pain. Secondary endpoints specific to the main group: : * Prevalence ratio of diabetes and prediabetes calculated for: * Clinical, paraclinical parameters (Oral examination, Muscle strength,Advanced glycation products) and anthropometric parameters (medical history, height, weight, BMI, Waist and hip circumference, Neck circumference, body composition measurement, Systolic and diastolic blood pressure, Unipedal stance test). * Biological (blood and genetic). * Behavioural/environmental predictors: (socio-economic status, physical activity(RICCI GAGNON), diet(HDI), quality of life (MQLI), stress-anxiety(PSS), toxic habits, fragility(FRIED) ). * Assessment of the level of ageing * Biological Aging Marker: DNAmPhenoAge (DNA methylation phenotypic age) * Accelerated ageing: age regression DNAmPhenoAge on chronological age * Analysis of age-related parameters (inflammatory, renal, hormonal, body composition measurement, fragility, advanced glycation products, muscle strength) and correlation with methylation rate and DNAmPhenoAge. * Prevalence ratio of (pre)diabetes and accelerated aging according to socio-economic status * Evaluation of (pre)diabetes: fasting blood sugar * Accelerated Aging Assessment: DNAm PhenoAge * Social Status Assessment: EPICES Q1 to Q5 Score * Assessment of economic status: Income level Secondary endpoints specific to the subgroup: * Risk (OR) of (pre)diabetes and accelerated aging according to social, economic, cultural and marital status * Evaluation of (pre)diabetes: fasting blood sugar * Accelerated Aging Assessment: DNAmPhenoAge * Socio-economic and cultural criteria * Social status (EPICES score) * Economic status (income) * Cultural status (semi-directive interview) * Professional status (educational level, socio-professional category, marital status) * Risk (OR) of (pre)diabetes and accelerated aging for assessed exposures: * Evaluation of (pre)diabetes: fasting blood sugar * Accelerated Aging Assessment: DNAmPhenoAge * Exposure Assessment * Arterial Stiffness Index * Body composition (mineral density, lean mass, fat mass) (DEXA test) * Insomnia Severity Index (ISI) * Cognitive Status (MOCA) * Physical Activity (GPAQ Questionnaire) * Alcohol consumption (FACE) * Psychiatric disorders (MINI) * Fragility (REFS score) * Pain Scale (EVA)

Interventions

Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.

In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.

Sponsors

National Center for Precision Diabetic Medicine,PreciDIAB
CollaboratorUNKNOWN
Institut Pasteur de Lille
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult, male or female * Consultant for the health prevention examination at the Examination Centre of Health of the Institut Pasteur of Lille * Available to follow the constraints generated by the study * Signature of the informed consent * Status of insured person in France

Exclusion criteria

* Participation in another clinical study or in a period of exclusion from another study * Adult deprived of liberty or under judicial protection * Impediment to give the free and informed consent (understanding, persons under guardianship/curators, etc.) * Incompatible scheduling * Other reason (state of health or concomitant treatments,...) considered by the principal investigator or a qualified co-investigator not compatible with the proper conduct of the clinical study

Design outcomes

Primary

MeasureTime frameDescription
Fasting glucose value according to the level of precariousnessDay 0Glycemia in g/L Level of precariousness given by EPICES score

Secondary

MeasureTime frameDescription
Prevalence ratio of (pre)diabetes calculated for clinical, biological and behavioral/environmental explanatory variablesDay 0In %
Assessment of the level of accelerated ageing (DNAmPhenoAge)Day 0In units of years
Prevalence ratio of (pre) diabetes and accelerated aging according to the socio-economic statusDay 0In %
Risk (odds Ratio) of (pre) diabetes and accelerated aging according to social, economic, cultural and professional statusUntil Day 90Without units
Risk (odds Ratio) of (pre) diabetes and accelerated aging for assessed exposuresUntil Day 90Without units

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026